LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
Keyword(s):
Phase Ii
◽
2021 ◽
Vol 85
(3)
◽
pp. AB89
2020 ◽
Vol 83
(6)
◽
pp. AB59
2021 ◽
Vol Publish Ahead of Print
◽
Keyword(s):
2019 ◽
Vol 41
(10)
◽
pp. 711-717
◽
Keyword(s):
2017 ◽
Vol 27
(4)
◽
pp. 386-392
◽